Tranexamic Acid for reduction of intra- and postoperative TRansfusion requirements in elective Abdominal surgery (TATRA): study protocol for an investigator-initiated, multicenter, double-blind, placebo-controlled, randomized superiority trial with two parallel groups.
Tranexamic Acid
/ administration & dosage
Humans
Double-Blind Method
Antifibrinolytic Agents
/ administration & dosage
Multicenter Studies as Topic
Elective Surgical Procedures
Randomized Controlled Trials as Topic
Blood Transfusion
Abdomen
/ surgery
Blood Loss, Surgical
/ prevention & control
Postoperative Hemorrhage
/ prevention & control
Treatment Outcome
Time Factors
Equivalence Trials as Topic
Abdominal surgery
Blood transfusion
Patient blood management
Perioperative bleeding
Tranexamic acid
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
08
07
2024
accepted:
08
10
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
Intra- and postoperative hemorrhage is a relevant problem in major abdominal surgery, leading to acute anemia and necessitating transfusion of packed red blood cells. It is estimated that in 30% of abdominal surgeries, intra- or postoperative transfusion is required. Transfusion potentially has detrimental health effects and poses a considerable socioeconomic burden. Tranexamic acid, a lysine analog inhibiting plasminogen activation and providing clot stability, has been used to reduce hemorrhage. While there is ample evidence in other surgical disciplines, it is almost completely lacking in abdominal surgery. This multicenter double-blind parallel group randomized superiority trial will compare tranexamic acid (loading dose 1000 mg over 10 min prior to skin incision, maintenance dose 125 mg/h continuously until skin closure or until 1000 mg have been administered) to placebo in patients ≥ 18 years undergoing elective esophagectomy, gastrectomy, colectomy, rectal resection, pancreatic resection, or hepatectomy. The primary efficacy endpoint is the intra- or postoperative transfusion of at least one unit of packed red blood cells. Key secondary endpoints are the number of transfused units per patient, estimated intraoperative blood loss, postoperative complications/mortality, length of hospital stay, operation/anesthesia time, D-dimer levels, and quality of life. Sample size calculation is based on the assumption that in the control group, 30% of patients require transfusion while the intervention achieves a risk reduction of 33%, reducing the probability to 20%. With a type one error of 5% and a power of 90%, using a two-sided χ If the proposed trial yielded positive results, the routine use of tranexamic acid in major abdominal surgery would be supported. This would avoid acute anemia with detrimental effects such as tissue hypoxia and organ injury, as well as the negative immediate and delayed effects of transfusions. EU CT Nr: 2023-509970-43-01, NCT06414031 . Registered on 10 May 2024.
Sections du résumé
BACKGROUND
BACKGROUND
Intra- and postoperative hemorrhage is a relevant problem in major abdominal surgery, leading to acute anemia and necessitating transfusion of packed red blood cells. It is estimated that in 30% of abdominal surgeries, intra- or postoperative transfusion is required. Transfusion potentially has detrimental health effects and poses a considerable socioeconomic burden. Tranexamic acid, a lysine analog inhibiting plasminogen activation and providing clot stability, has been used to reduce hemorrhage. While there is ample evidence in other surgical disciplines, it is almost completely lacking in abdominal surgery.
METHODS
METHODS
This multicenter double-blind parallel group randomized superiority trial will compare tranexamic acid (loading dose 1000 mg over 10 min prior to skin incision, maintenance dose 125 mg/h continuously until skin closure or until 1000 mg have been administered) to placebo in patients ≥ 18 years undergoing elective esophagectomy, gastrectomy, colectomy, rectal resection, pancreatic resection, or hepatectomy. The primary efficacy endpoint is the intra- or postoperative transfusion of at least one unit of packed red blood cells. Key secondary endpoints are the number of transfused units per patient, estimated intraoperative blood loss, postoperative complications/mortality, length of hospital stay, operation/anesthesia time, D-dimer levels, and quality of life. Sample size calculation is based on the assumption that in the control group, 30% of patients require transfusion while the intervention achieves a risk reduction of 33%, reducing the probability to 20%. With a type one error of 5% and a power of 90%, using a two-sided χ
DISCUSSION
CONCLUSIONS
If the proposed trial yielded positive results, the routine use of tranexamic acid in major abdominal surgery would be supported. This would avoid acute anemia with detrimental effects such as tissue hypoxia and organ injury, as well as the negative immediate and delayed effects of transfusions.
TRIAL REGISTRATION
BACKGROUND
EU CT Nr: 2023-509970-43-01, NCT06414031 . Registered on 10 May 2024.
Identifiants
pubmed: 39425234
doi: 10.1186/s13063-024-08541-8
pii: 10.1186/s13063-024-08541-8
doi:
Substances chimiques
Tranexamic Acid
6T84R30KC1
Antifibrinolytic Agents
0
Banques de données
ClinicalTrials.gov
['NCT06414031']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
695Informations de copyright
© 2024. The Author(s).
Références
Ecker BL, Simmons KD, Zaheer S, Poe SL, Bartlett EK, Drebin JA, et al. Blood Transfusion in Major Abdominal Surgery for Malignant Tumors: A Trend Analysis Using the National Surgical Quality Improvement Program. JAMA Surg. 2016;151(6):518–25.
doi: 10.1001/jamasurg.2015.5094
pubmed: 26763765
Saadat LV, Goldman DA, Gonen M, Soares KC, Wei AC, Balachandran VP, et al. Timing of Complication and Failure to Rescue after Hepatectomy: Single-Institution Analysis of 28 Years of Hepatic Surgery. J Am Coll Surg. 2021;233(3):415–25.
doi: 10.1016/j.jamcollsurg.2021.04.033
pubmed: 34029677
pmcid: 8503809
Abdelsattar ZM, Habermann E, Borah BJ, Moriarty JP, Rojas RL, Blackmon SH. Understanding Failure to Rescue After Esophagectomy in the United States. Ann Thorac Surg. 2020;109(3):865–71.
doi: 10.1016/j.athoracsur.2019.09.044
pubmed: 31706867
Kleinerüschkamp AG, Zacharowski K, Ettwein C, Müller MM, Geisen C, Weber CF, et al. Cost analysis of patient blood management. Anaesthesist. 2016;65(6):438–48.
doi: 10.1007/s00101-016-0152-9
pubmed: 27160419
Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;2006(1):CD005033.
Hopewell S, Omar O, Hyde C, Yu LM, Doree C, Murphy MF. A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010. BMJ Open. 2013;3:e02154.
Franchini M, Marano G, Veropalumbo E, Masiello F, Pati I, Candura F, et al. Patient Blood Management: a revolutionary approach to transfusion medicine. Blood Transfus. 2019;17(3):191–5.
pubmed: 31246561
pmcid: 6596379
Amer KM, Rehman S, Amer K, Haydel C. Efficacy and Safety of Tranexamic Acid in Orthopaedic Fracture Surgery: A Meta-Analysis and Systematic Literature Review. J Orthop Trauma. 2017;31(10):520–5.
doi: 10.1097/BOT.0000000000000919
pubmed: 28938282
Cheriyan T, Maier SP, Bianco K, Slobodyanyuk K, Rattenni RN, Lafage V, et al. Efficacy of tranexamic acid on surgical bleeding in spine surgery: a meta-analysis. Spine J. 2015;15(4):752–61.
doi: 10.1016/j.spinee.2015.01.013
pubmed: 25617507
Haj-Younes B, Sivakumar BS, Wang M, An VV, Lorentzos P, Adie S. Tranexamic acid in hip fracture surgery: A systematic review and meta-analysis. J Orthop Surg (Hong Kong). 2020;28(1):2309499019887995.
doi: 10.1177/2309499019887995
pubmed: 31835969
Qi YM, Wang HP, Li YJ, Ma BB, Xie T, Wang C, et al. The efficacy and safety of intravenous tranexamic acid in hip fracture surgery: A systematic review and meta-analysis. J Orthop Translat. 2019;19:1–11.
doi: 10.1016/j.jot.2019.03.007
pubmed: 31844608
pmcid: 6896672
Tian L, Li X, He L, Ji H, Yao Y. Hemostatic effects of tranexamic acid in cardiac surgical patients with antiplatelet therapy: a systematic review and meta-analysis. Perioper Med (Lond). 2024;13(1):58.
doi: 10.1186/s13741-024-00418-3
pubmed: 38886771
Longo MA, Cavalheiro BT, de Oliveira Filho GR. Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery. J Clin Anesth. 2018;48:32–8.
doi: 10.1016/j.jclinane.2018.04.014
pubmed: 29727761
Topsoee MF, Settnes A, Ottesen B, Bergholt T. A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery. Int J Gynaecol Obstet. 2017;136(2):120–7.
doi: 10.1002/ijgo.12047
pubmed: 28099726
Nikolaou VS, Masouros P, Floros T, Chronopoulos E, Skertsou M, Babis GC. Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial. Bone Joint J. 2021;103-b(3):442–8.
Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 2013;100(10):1271–9.
doi: 10.1002/bjs.9193
pubmed: 23839785
Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344: e3054.
doi: 10.1136/bmj.e3054
pubmed: 22611164
pmcid: 3356857
Taeuber I, Weibel S, Herrmann E, Neef V, Schlesinger T, Kranke P, et al. Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Surg. 2021;156(6): e210884.
doi: 10.1001/jamasurg.2021.0884
pubmed: 33851983
pmcid: 8047805
Devereaux PJ, Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med. 2022;386(21):1986–97.
doi: 10.1056/NEJMoa2201171
pubmed: 35363452
Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiol. 1996;85(5):1043–8 discussion 30A-31A.
doi: 10.1097/00000542-199611000-00012
Dalmau A, Sabaté A, Acosta F, Garcia-Huete L, Koo M, Sansano T, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg. 2000;91(1):29–34.
pubmed: 10866882
Wu CC, Ho WM, Cheng SB, Yeh DC, Wen MC, Liu TJ, et al. Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a “blood transfusion”-free hepatectomy. Ann Surg. 2006;243(2):173–80.
doi: 10.1097/01.sla.0000197561.70972.73
pubmed: 16432349
pmcid: 1448924
Kaspar M, Ramsay MA, Nguyen AT, Cogswell M, Hurst G, Ramsay KJ. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg. 1997;85(2):281–5.
pubmed: 9249100
Yassen KA, Bellamy MC, Sadek SA, Webster NR. Tranexamic acid reduces blood loss during orthotopic liver transplantation. Clin Transplant. 1993;7:453–8.
doi: 10.1111/j.1399-0012.1993.tb00722.x
Jaffer AA, Karanicolas PJ, Davis LE, Behman R, Hanna SS, Law CH, et al. The impact of tranexamic acid on administration of red blood cell transfusions for resection of colorectal liver metastases. HPB (Oxford). 2021;23(2):245–52.
doi: 10.1016/j.hpb.2020.06.004
pubmed: 32641281
Grass F, Braafladt S, Alabbad J, Lovely JK, Kelley SR, Mathis KL, et al. The effects of tranexamic acid on blood loss and transfusion rate in colorectal surgery. Am J Surg. 2019;218(5):876–80.
doi: 10.1016/j.amjsurg.2019.03.013
pubmed: 30926155
Ishii K, Yokoyama Y, Yonekawa Y, Hayashi D, Kinoshita F, Kuwatsuka Y, et al. Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial. Br J Surg. 2023;110(2):159–65.
doi: 10.1093/bjs/znac382
pubmed: 36379883
Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie): Deutscher Ärzteverlag; 2023. Available from: https://www.bundesaerztekammer.de/fileadmin/user_upload/BAEK/Themen/Medizin_und_Ethik/Richtlinie-Haemotherapie-2023_neu2.pdf . Accessed 01 Jul 2024.
Kim Y, Bagante F, Gani F, Ejaz A, Xu L, Wasey JO, et al. Nomogram to predict perioperative blood transfusion for hepatopancreaticobiliary and colorectal surgery. Br J Surg. 2016;103(9):1173–83.
doi: 10.1002/bjs.10164
pubmed: 27222214